Topical clindamycin for acne vulgaris: analysis of gastrointestinal events
Conclusions: According to pharmacovigilance data, the rate of GI adverse drug reactions with topical clindamycin-containing products was 0.000045% (64/141,084,533). Results from two retrospective medical record studies of patients with AV indicated that physicians prescribe topical clindamycin equally to patients with or without inflammatory bowel disease history, and that rates of pseudomembranous colitis in these patients were low. In 8 published pivotal clinical trials of topical clindamycin for AV, GI AEs were reported in 1.4% of participants. Limitations include under/inaccurate reporting of AEs or prescription data a...
Source: Journal of Dermatological Treatment - April 3, 2024 Category: Dermatology Authors: Natalia M Pelet Del Toro Andrew Strunk Jashin J Wu Linda Stein Gold James Q Del Rosso Robert T Brodell George Han Source Type: research
Treatments for Moderate-to-Severe Acne Vulgaris: A Systematic Review and Network Meta-analysis
CONCLUSIONS: Based on this SLR/NMA, topical triple-agent FDC gel was the most efficacious and safe treatment for moderate-to-severe acne. J Drugs Dermatol. 2024;23(4): doi:10.36849/JDD.8148.PMID:38564399 | DOI:10.36849/JDD.8148 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - April 2, 2024 Category: Dermatology Authors: Julie C Harper Hilary Baldwin Saswata Paul Choudhury Deepti Rai Bikramaditya Ghosh Md Sohai Aman Abhra R Choudhury Sekhar Kumar Dutta Debalina Dey Subrata Bhattacharyya Tina Lin George Joseph Ankur A Dashputre Jerry K L Tan Source Type: research
